Welcome to our dedicated page for Zymeworks news (Ticker: ZYME), a resource for investors and traders seeking the latest updates and insights on Zymeworks stock.
Zymeworks Inc. (Nasdaq: ZYME) generates frequent news flow as a biotechnology and clinical-stage biopharmaceutical company managing licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics. Company announcements highlight its focus on difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, and its integrated model that combines internal R&D with an asset and royalty aggregation strategy.
News about Zymeworks often centers on clinical trial progress and key data readouts. A major theme is the development of Ziihera ® (zanidatamab-hrii), a HER2-targeted bispecific antibody engineered using the company’s Azymetric™ technology. Press releases have detailed positive Phase 3 HERIZON-GEA-01 results in first-line HER2-positive gastroesophageal adenocarcinoma, as well as regulatory approvals for previously treated HER2-positive biliary tract cancer in the U.S., Europe, and China. Updates also cover the advancement of partnered programs like pasritamig with Johnson & Johnson Innovative Medicine and early-stage data from wholly owned ADC candidates such as ZW191 and ZW251.
Investors following ZYME news can also expect regular coverage of strategic and corporate developments. The company reports on its evolving royalty- and asset-focused strategy, share repurchase authorizations, milestone and royalty revenues from partners, and leadership and board appointments designed to support capital allocation and partnership execution. Participation in major medical and investor conferences, such as ASCO GI and the J.P. Morgan Healthcare Conference, is another recurring topic in its news releases.
This news feed provides a centralized view of Zymeworks’ clinical milestones, partnership updates, financial and strategic announcements, and governance changes, offering context for how the company is executing its stated goal of building a diversified portfolio of revenue-generating healthcare assets alongside an active R&D engine.
Zymeworks Inc. (NYSE: ZYME) has announced the adoption of a limited-duration shareholder rights plan in response to an unsolicited acquisition proposal from All Blue Falcons FZE. This Rights Plan aims to protect shareholders by ensuring that any potential acquisition reflects the full value of their investment. It allows the board time to evaluate proposals while reducing the risk of control through market accumulation. The Rights Plan can be activated if ownership surpasses 10% or 20% for passive investors and will expire on June 8, 2023.
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, will participate in the Jefferies Healthcare Conference on June 8-9. Management will hold one-on-one meetings and present on June 8 at 9:30 a.m. ET in New York, NY. The presentation will be available on Zymeworks’ website. Zymeworks focuses on next-generation multifunctional biotherapeutics, with lead candidate zanidatamab targeting HER2-positive solid tumors and ZW49 in Phase 1 development. For more details, visit their clinical trials page.
Zymeworks Inc. reported promising clinical results for its bispecific antibody, zanidatamab, at the ASCO Annual Meeting. In advanced HER2-positive breast cancer, the treatment demonstrated a 90.5% confirmed objective response rate (cORR). In a separate study for gastric adenocarcinoma, zanidatamab combined with chemotherapy yielded a 75.8% cORR and a 100% disease control rate (DCR). The company plans to host an analyst and investor call on June 6 to discuss these findings and the ongoing clinical development strategy.
Zymeworks (NYSE: ZYME) announced that its Board unanimously rejected an unsolicited proposal from activist shareholder All Blue Falcons FZE to acquire the company at $10.50 per share, citing substantial undervaluation. The Board emphasized its focus on advancing its clinical assets zanidatamab and ZW49, with key data expected through 2023. Zymeworks aims to enhance its financial position and pursue strategic partnerships to bolster growth and shareholder value. The rejection followed previous tensions with All Blue regarding financing proposals and company direction.
All Blue Capital announced the appointment of Dr. Siddhartha Mukherjee as Medical Advisor to bolster its acquisition proposal for Zymeworks at $10.50 per share. Dr. Mukherjee, a Pulitzer Prize-winning author and cancer expert, aims to help turnaround Zymeworks, which has faced significant challenges. All Blue is urging Zymeworks' Board to engage with their proposal, citing a pattern of value erosion due to previous missteps. If the Board does not respond, All Blue plans to take action to protect shareholders' interests.
Zymeworks Inc. (NYSE: ZYME) announced the completion of patient enrollment ahead of schedule in its pivotal trial (HERIZON-BTC-01) for zanidatamab, a therapy targeting HER2 in biliary tract cancers. This achievement reinforces their commitment to developing new treatments. Financially, revenue rose to $1.9 million from $0.6 million year-over-year, though net losses increased to $72.6 million. The company plans to enhance funding through collaborations while controlling expenses. Zymeworks aims to submit two new IND applications by 2024 and will present data at ASCO in June.
On May 3, 2022, All Blue Capital announced that Dr. Alan Barge, an expert in oncology and biopharmaceutical drug development, will serve as an advisor during their proposed acquisition of Zymeworks (NYSE: ZYME). All Blue has proposed acquiring Zymeworks for $10.50 per share, totaling approximately $773 million in equity value. The aim is to reverse Zymeworks' recent underperformance and enhance operational performance. Dr. Barge's extensive background, including his experience at AstraZeneca, is expected to contribute significantly to Zymeworks’ turnaround.
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright Global Investment Conference from May 24-26. They will hold virtual one-on-one meetings and a corporate presentation on May 24 at 7 a.m. ET. This presentation will be accessible via Zymeworks’ website. Zymeworks focuses on developing next-generation multifunctional biotherapeutics, with lead candidate zanidatamab currently in multiple trials for solid tumors expressing HER2. For more details, visit their corporate site.
Zymeworks Inc. (NYSE: ZYME) has received an unsolicited, non-binding proposal from All Blue Falcons FZE (ABF) to acquire the company for $10.50 per share in cash. The Zymeworks board will review this proposal carefully to determine the best course of action for the company and its shareholders. No formal offer has been made yet, and shareholders do not need to take any action at this time. Zymeworks focuses on developing multifunctional biotherapeutics, including its leading clinical candidates, zanidatamab and ZW49.
Zymeworks Inc. (NYSE: ZYME) has completed enrollment in its pivotal HERIZON-BTC-01 clinical trial, assessing the antitumor efficacy of zanidatamab for patients with advanced HER2-amplified biliary tract cancers. Results are anticipated in early 2023. This trial addresses a significant need, as over 210,000 new cases of biliary tract cancers are diagnosed globally each year, with limited treatment options available. Zanidatamab has received Breakthrough Therapy designation from the FDA for this indication, highlighting its potential to improve patient outcomes.